Aortic Regurgitation
43
8
13
13
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.7%
2 terminated out of 43 trials
86.7%
+0.1% vs benchmark
7%
3 trials in Phase 3/4
23%
3 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (43)
The JenaValve ALIGN-AR LVAD Registry
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease
DELINEATE-Prospective
Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
TAVR for Aortic Regurgitation Under TTE Guidance
TAVR for Aortic Regurgitation Under TEE Guidance
3-Dimensional Simulation Guided Transcatheter Aortic Valve Replacement in Aortic Regurgitation(DIGITAL)
TRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System
Comparative Imaging Assessment of Valvular Heart Disease
Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
CT-evaluation of Coronary Ostia Height After Surgical Aortic Valve Replacement.
Mild and Moderate Aortic Regurgitation: Risk Factors for Progress and Outcome
Early Feasibility Study of Surgical Implantation of a Polymer Prosthetic Mitral and Aortic Valve
J-Valve TF Early Feasibility Study
The Fate of Aortic Valve After SAS Surgery in Children
Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population